Jun 2026 (Q2 FY26) — Jul 30, 2026
Labcorp Q2 FY26 — Strong Revenue Growth and Raised Full-Year Guidance
Read the full callLabcorp (LH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Labcorp earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 3,731 | +5.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.1 | +0.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 299 | +25.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$318.83 +0.28% · +$0.88
Performance +11.5% 1Y
1Y: $285.94 on 17 Oct 2025 → $318.83. High $339.34 (24 Aug 2026), low $246.64 (6 Nov 2025).
- Previous close
- $317.95
- 52-week range
- $246.64 – $339.34
- One year
- +9.59%
Overview
- Symbol
- LH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Labcorp earnings calls (LH)
Financials
What the filings say
Net profit, year on year: +26% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,282 | 3,329 | 3,345 | 3,527 | 3,564 | 3,516 | 3,538 | 3,731 |
| Operating profit | 254 | 217 | 326 | 395 | 397 | 268 | 381 | 452 |
| Operating margin | 7.7% | 6.5% | 9.8% | 11.2% | 11.1% | 7.6% | 10.8% | 12.1% |
| Interest | 50 | 63 | 56 | 57 | 56 | 55 | 55 | 61 |
| Net profit | 169 | 143 | 213 | 238 | 261 | 165 | 278 | 299 |
| EPS ($ per share) | 2.02 | — | 2.54 | 2.85 | 3.14 | — | 3.37 | 3.66 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 12 | 9 | 9 | 9 | 8 | 8 | 8 | 8 |
| Reserves | 7,157 | 7,981 | 9,479 | 10,457 | 10,582 | 7,888 | 8,303 | 8,640 |
| Total liabilities | 9,195 | 10,459 | 10,614 | 10,091 | 10,040 | 8,835 | 10,313 | 9,756 |
| Fixed assets | 1,740 | 2,637 | 2,730 | 2,815 | 2,794 | 2,912 | 3,045 | 3,082 |
| Total assets | 16,185 | 18,046 | 20,072 | 20,385 | 20,155 | 16,725 | 18,379 | 18,393 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,305 | 1,445 | 2,135 | 3,110 | 1,956 | 1,328 | 1,586 | 1,641 |
| Cash from investing | 207 | -1,283 | -643 | -885 | -1,652 | -1,171 | -1,367 | -1,194 |
| Cash from financing | -1,390 | -253 | -517 | -2,066 | -1,322 | -59 | 780 | -1,457 |
| Net cash flow | 110 | -89 | 983 | 152 | -1,043 | 107 | 982 | -986 |
| Capital expenditure | -380 | -400 | -382 | -421 | -429 | -454 | -490 | -434 |
| Free cash flow | 926 | 1,045 | 1,754 | 2,688 | 1,527 | 874 | 1,096 | 1,206 |
LH revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | 78% | 78% | 79% | 78% | 78% | 78% | 78% | 78% | +5.5% |
| Biopharma Laboratory Services | — | — | 22% | 22% | 22% | 23% | 22% | 22% | +6.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 83% ↓ 1 pt
As LH cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
150 filings between Oct 31, 2025 and Aug 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$13.70M
21 sales by 10 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 55
- Option exercise — converted options into shares
- 60
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Schechter Adam H | — | $8.44M | Aug 11, 2026 |
| Parham Richelle P | — | $1.78M | Oct 31, 2025 |
| Wilkinson Peter J | — | $1.06M | Aug 3, 2026 |
| ANDERSON KERRII B | — | $954.1K | Aug 17, 2026 |
| Caveney Brian J | — | $429.5K | Feb 24, 2026 |
| Meltzer Jonathan C | — | $298.8K | Mar 27, 2026 |
| Summy Amy B. | — | $283.4K | Aug 4, 2026 |
| Kyle Kathryn W | — | $227.4K | Jul 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 17, 2026 | ANDERSON KERRII B Director | Sale 10b5-1 plan | 3,000 | $954.1K |
| Aug 11, 2026 | Schechter Adam H President & CEO | Sale 10b5-1 plan | 4,669 | $1.50M |
| Aug 4, 2026 | Summy Amy B. EVP, Chief Marketing Officer | Sale | 924 | $283.4K |
| Aug 3, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Option exercise | 1,338 | $280.0K |
| Aug 3, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Sale | 82 | $25.4K |
| Aug 3, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Sale | 1,338 | $413.8K |
| Jul 2, 2026 | Vaughn Bryan T EVP and President, Diagnostics | Sale 10b5-1 plan | 234 | $67.0K |
| Jul 2, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Sale 10b5-1 plan | 92 | $26.3K |
| Jul 1, 2026 | Vaughn Bryan T EVP and President, Diagnostics | Option exercise 10b5-1 plan | 327 | — |
| Jul 1, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Tax withheld 10b5-1 plan | 73 | $20.7K |
| Jul 1, 2026 | Vaughn Bryan T EVP and President, Diagnostics | Tax withheld 10b5-1 plan | 93 | $26.4K |
| Jul 1, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Option exercise 10b5-1 plan | 256 | — |
| Jun 8, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Sale 10b5-1 plan | 762 | $201.1K |
| May 11, 2026 | Schechter Adam H President & CEO | Sale 10b5-1 plan | 5,903 | $1.50M |
| Mar 27, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Sale 10b5-1 plan | 1,633 | $436.1K |
| Mar 27, 2026 | Meltzer Jonathan C EVP, Operations | Sale 10b5-1 plan | 839 | $224.1K |
| Mar 26, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Award 10b5-1 plan | 2,388 | $0 |
| Mar 26, 2026 | Vaughn Bryan T EVP, Diagnostics | Tax withheld | 451 | $121.0K |
| Mar 26, 2026 | Vaughn Bryan T EVP, Diagnostics | Award | 1,584 | $0 |
| Mar 26, 2026 | van der Vaart Sandra D EVP, Corporate Affairs | Award | 6,382 | $0 |
| Mar 26, 2026 | Summy Amy B. EVP, Chief Marketing Officer | Award | 3,994 | $0 |
| Mar 26, 2026 | Summy Amy B. EVP, Chief Marketing Officer | Tax withheld | 1,836 | $492.7K |
| Mar 26, 2026 | Bailey Megan D. EVP, Pres, Central Labs & Intl | Tax withheld | 481 | $129.1K |
| Mar 26, 2026 | Oyegunwa Akinbolade EVP, CIO & CTO | Award | 1,340 | $0 |
| Mar 26, 2026 | Bailey Megan D. EVP, Pres, Central Labs & Intl | Award | 1,184 | $0 |
| Mar 26, 2026 | van der Vaart Sandra D EVP, Corporate Affairs | Tax withheld | 2,722 | $730.5K |
| Mar 26, 2026 | GRAHAM ANITA Z EVP, CHRO | Tax withheld | 2,879 | $772.7K |
| Mar 26, 2026 | GRAHAM ANITA Z EVP, CHRO | Award | 6,604 | $0 |
| Mar 26, 2026 | Schroeder Mark S EVP, Pres Diagnostics & COO | Tax withheld | 1,468 | $394.0K |
| Mar 26, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Tax withheld 10b5-1 plan | 755 | $202.6K |
| Mar 26, 2026 | Meltzer Jonathan C EVP, Operations | Tax withheld 10b5-1 plan | 711 | $190.8K |
| Mar 26, 2026 | Meltzer Jonathan C EVP, Operations | Award 10b5-1 plan | 2,388 | $0 |
| Mar 26, 2026 | Schroeder Mark S EVP, Pres Diagnostics & COO | Award | 9,304 | $0 |
| Mar 26, 2026 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Tax withheld | 863 | $231.6K |
| Mar 26, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Tax withheld | 451 | $121.0K |
| Mar 26, 2026 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Award | 1,986 | $0 |
| Mar 26, 2026 | Schroeder Mark S EVP, Pres Diagnostics & COO | Tax withheld | 4,600 | $1.23M |
| Mar 26, 2026 | Schroeder Mark S EVP, Pres Diagnostics & COO | Award | 2,968 | $0 |
| Mar 26, 2026 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Tax withheld | 4,042 | $1.08M |
| Mar 26, 2026 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Award | 9,304 | $0 |
| Mar 26, 2026 | Kyle Kathryn W EVP, Chief Legal Officer | Award | 1,584 | $0 |
| Mar 26, 2026 | Schechter Adam H President & CEO | Award | 58,470 | $0 |
| Mar 26, 2026 | Oyegunwa Akinbolade EVP, CIO & CTO | Tax withheld | 382 | $102.5K |
| Mar 26, 2026 | Schechter Adam H President & CEO | Tax withheld | 26,106 | $7.01M |
| Mar 3, 2026 | Schechter Adam H President & CEO | Sale | 8,705 | $2.44M |
| Feb 27, 2026 | van der Vaart Sandra D EVP, Corporate Affairs | Sale | 548 | $156.0K |
| Feb 24, 2026 | Caveney Brian J EVP, Pres of ED, CMO & CSO | Sale | 1,500 | $429.5K |
| Feb 19, 2026 | Wilkinson Peter J SVP, Chief Accounting Officer | Sale 10b5-1 plan | 666 | $185.1K |
| Feb 12, 2026 | Meltzer Jonathan C EVP, Operations | Sale 10b5-1 plan | 87 | $25.3K |
| Feb 11, 2026 | Davis Jeffrey A. Director | Option exercise | 897 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LABCORP HOLDINGS INC.
Free account. Everything above stays public.
Write why you follow LABCORP HOLDINGS INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading